BRPI0817482A2 - agentes terapêuticos para a doença do enxerto versus hospedeiro compreendendo um inbidor do receptor da interleucina 6 como substância ativa - Google Patents

agentes terapêuticos para a doença do enxerto versus hospedeiro compreendendo um inbidor do receptor da interleucina 6 como substância ativa

Info

Publication number
BRPI0817482A2
BRPI0817482A2 BRPI0817482A BRPI0817482A BRPI0817482A2 BR PI0817482 A2 BRPI0817482 A2 BR PI0817482A2 BR PI0817482 A BRPI0817482 A BR PI0817482A BR PI0817482 A BRPI0817482 A BR PI0817482A BR PI0817482 A2 BRPI0817482 A2 BR PI0817482A2
Authority
BR
Brazil
Prior art keywords
interleukin
active substance
therapeutic agents
host disease
versus host
Prior art date
Application number
BRPI0817482A
Other languages
English (en)
Inventor
Masahiko Mihara
Yoichiro Moriya
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40526199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0817482(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to BR122019021238A priority Critical patent/BR122019021238B8/pt
Publication of BRPI0817482A2 publication Critical patent/BRPI0817482A2/pt
Publication of BRPI0817482B1 publication Critical patent/BRPI0817482B1/pt
Publication of BRPI0817482B8 publication Critical patent/BRPI0817482B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0817482A 2007-10-02 2008-10-01 uso de um anticorpo do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd) BRPI0817482B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019021238A BR122019021238B8 (pt) 2007-10-02 2008-10-01 uso de um inibidor do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007258810 2007-10-02
PCT/JP2008/067835 WO2009044774A1 (ja) 2007-10-02 2008-10-01 インターロイキン６受容体阻害剤を有効成分とする移植片対宿主病治療剤

Publications (3)

Publication Number Publication Date
BRPI0817482A2 true BRPI0817482A2 (pt) 2015-09-29
BRPI0817482B1 BRPI0817482B1 (pt) 2020-01-14
BRPI0817482B8 BRPI0817482B8 (pt) 2021-05-25

Family

ID=40526199

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122019021238A BR122019021238B8 (pt) 2007-10-02 2008-10-01 uso de um inibidor do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
BRPI0817482A BRPI0817482B8 (pt) 2007-10-02 2008-10-01 uso de um anticorpo do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122019021238A BR122019021238B8 (pt) 2007-10-02 2008-10-01 uso de um inibidor do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)

Country Status (12)

Country Link
US (1) US8529895B2 (pt)
EP (1) EP2196220B1 (pt)
JP (1) JP5264752B2 (pt)
KR (1) KR101601986B1 (pt)
CN (1) CN101815532B (pt)
AU (1) AU2008308163B2 (pt)
BR (2) BR122019021238B8 (pt)
CA (1) CA2701155C (pt)
MX (1) MX2010003139A (pt)
RU (1) RU2490025C2 (pt)
TW (1) TWI468173B (pt)
WO (1) WO2009044774A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322216A1 (en) 1997-03-21 2011-05-18 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
CN101721362B (zh) * 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2005090405A1 (ja) * 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha インターロイキン－６受容体に対するヒト型化抗体のサブタイプ
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR101680906B1 (ko) 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
SI2493922T1 (sl) 2009-10-26 2017-06-30 F. Hoffmann-La Roche Ag Postopek za proizvodnjo glikoziliranega imunoglobulina
KR20190120439A (ko) 2010-11-08 2019-10-23 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
BR112015032960B1 (pt) 2013-07-04 2021-01-05 F. Hoffmann-La Roche Ag imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
AU2015329625B2 (en) 2014-10-10 2018-04-05 Pfizer Inc. Synergistic auristatin combinations
CA2972393A1 (en) * 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
US10697883B2 (en) 2015-05-19 2020-06-30 National Center Of Neurology And Psychiatry Method for determining application of therapy to multiple sclerosis (MS) patient
WO2017147169A1 (en) 2016-02-22 2017-08-31 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CN117045784A (zh) 2016-12-14 2023-11-14 比奥拉治疗股份有限公司 使用利用可摄入装置释放的il-12/il-23抑制剂治疗胃肠道疾病
CN110603057A (zh) 2017-03-17 2019-12-20 俄亥俄州创新基金会 用于递送化学预防剂的纳米颗粒
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
US20210363233A1 (en) 2018-06-20 2021-11-25 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
EP3957324A4 (en) 2019-04-17 2023-02-08 Hiroshima University THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR
WO2024126805A1 (en) 2022-12-15 2024-06-20 Aarhus Universitet Synthetic activation of multimeric transmembrane receptors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
CA1341152C (en) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
ES2093017T3 (es) 1989-07-20 1996-12-16 Tadamitsu Kishimoto Anticuerpo contra el receptor de la interleuquina-6 humana.
JPH03155795A (ja) 1989-11-13 1991-07-03 Chuzo Kishimoto マウス・インターロイキン―６レセプター蛋白質
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5795965A (en) * 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
FR2694767B1 (fr) 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
AU7967294A (en) * 1993-10-06 1995-05-01 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
EP0800829B2 (en) * 1994-12-29 2012-07-25 Chugai Seiyaku Kabushiki Kaisha Use of a pm-1 antibody or of a mh 166 antibody for enhancing the anti-tumor effect of cisplatin or carboplatin
WO1996030394A1 (en) 1995-03-31 1996-10-03 Jakob Bohr Method for protein folding
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
JPWO2002074298A1 (ja) * 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
PT2308888T (pt) 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
US20040071666A1 (en) * 2002-05-24 2004-04-15 The Regents Of The University Of Michigan Compositions and methods related to graft-versus-host disease
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
TWI438208B (zh) 2007-01-23 2014-05-21 中外製藥股份有限公司 抑制慢性排斥反應之藥劑

Also Published As

Publication number Publication date
JPWO2009044774A1 (ja) 2011-02-10
CN101815532B (zh) 2012-08-15
EP2196220A4 (en) 2011-12-21
BRPI0817482B1 (pt) 2020-01-14
RU2010117171A (ru) 2011-11-10
WO2009044774A1 (ja) 2009-04-09
TWI468173B (zh) 2015-01-11
RU2490025C2 (ru) 2013-08-20
BRPI0817482B8 (pt) 2021-05-25
EP2196220A1 (en) 2010-06-16
CA2701155C (en) 2016-11-22
US8529895B2 (en) 2013-09-10
CN101815532A (zh) 2010-08-25
AU2008308163A1 (en) 2009-04-09
KR101601986B1 (ko) 2016-03-17
BR122019021238B1 (pt) 2021-02-23
BR122019021238B8 (pt) 2021-07-27
KR20100075591A (ko) 2010-07-02
CA2701155A1 (en) 2009-04-09
MX2010003139A (es) 2010-04-07
TW200932262A (en) 2009-08-01
US20100255007A1 (en) 2010-10-07
JP5264752B2 (ja) 2013-08-14
AU2008308163B2 (en) 2013-03-21
HK1145288A1 (en) 2011-04-15
EP2196220B1 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
BRPI0817482A2 (pt) agentes terapêuticos para a doença do enxerto versus hospedeiro compreendendo um inbidor do receptor da interleucina 6 como substância ativa
CY2020036I1 (el) Δοσολογικο σχημα για εναν αγωνιστη του υποδοχεα s1p
BRPI0817075A2 (pt) núcleos de fármaco para liberação prolongada de agentes terapêuticos
BRPI0722082A2 (pt) Ligantes para imagiologia da inervação cardíaca
PT2355851T (pt) Novos lípidos e composições para a administração de agentes terapêuticos
EP2119444A4 (en) THERAPEUTIC AGENT FOR PAIN
DK2058317T3 (da) Aminophosphorsyreesterderivat og S1P receptormodulator indeholdende samme som aktiv ingrediens
PL3424932T3 (pl) Boronoftalidy do zastosowania terapeutycznego
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
DK3457135T3 (da) Behandlingsmuligheder til fabrys sygdom
PL2066179T3 (pl) Formulacje zawierające indoksakarb do miejscowego podawania na skórę
EP1981547A4 (en) STABLE THERAPEUTIC FORMULATIONS
BRPI0915093A2 (pt) conjugados para a administração de compostos biologicamente ativos
BRPI0821145A2 (pt) Agente terapêutico para prurido
EP2124556A4 (en) PHARMACEUTICAL COMPOSITIONS
DK2144905T3 (da) Terapeutiske midler
BRPI0821248A2 (pt) Inibidores de cinesina como fármacos terapêuticos para câncer
EP2035369A4 (en) THERAPEUTIC COMPOUNDS
MX2008007133A (es) Formulaciones enzimaticass mejoradas para alimentos para animales
DK2041128T3 (da) Substituerede gamma-lactamer som terapeutiske agenser
BRPI0719523A2 (pt) Derivado de espirocetal de tioglicose e uso deste como agente terapêutico para diabetes
BRPI0810091A2 (pt) Agentes fugicidas tópicos para tratar distúrbios ungueais
BRPI0809288A2 (pt) Formulações farmacêuticas auto-precipitação para a liberação modificada de um princípio ativo
BRPI0814210A2 (pt) Profármacos aminoacila como susbstância ativa farmacêutica para doenças tromboebólicas.
BRPI0813689A2 (pt) Profármacos de aminoacila como substância ativa medicamentosa para doenças tramboembólicas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF